Severe Extrapyramidal Syndrome Caused by Lurasidone Low Dose

Das, Soumitra; Andi, Bhaskaran Subramaniyam

doi:10.4103/jnrp.jnrp_571_17

Cited by 4 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Lurasidone-induced Parkinsonism, severe EPS, and rabbit syndrome had also been reported. [14][15][16] It was suggested that the high affinity of lurasidone for D2 receptors in the nigrostriatal tract, in combination with poor anticholinergic activity, could lead to drug-induced Parkinsonism. Even though earlier studies 4,5 reported fewer EPS with lurasidone, the meta-analysis by Leucht et al 17 identified that lurasidone was one among the five second-generation antipsychotics with significantly more EPS than placebo (OR = 2.46; 95% CI: 1.55-3.72).…”

Section: Discussionmentioning

confidence: 99%

Can Isolated Head Tremors Be an Extrapyramidal Symptom Associated with Lurasidone?—A Case Series

Suriya

Simiyon

Thilakan

et al. 2021

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Can Isolated Head Tremors Be an Extrapyramidal Symptom Associated with Lurasidone?—A Case Series

Suriya

Simiyon

Thilakan

et al. 2021

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Lurasidone

2018

Reactions Weekly

View full text Add to dashboard Cite

Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression

Modugula

Kumar

2020

CNSNDDT

View full text Add to dashboard Cite

Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression. However, emerging reports have indicated various adverse drug reactions with the use of lurasidone. Thus, in this article, we have analyzed the risk profile of lurasidone in the established therapeutic indication. A total of 419 studies were published from October 2010-July 2019 regarding lurasidone. After the inclusion and exclusion criteria, 17 studies were selected for the analysis of risk. The adverse drug reactions (ADRs) of these studies were categorized as per the innovator summary of product characteristics (SmPC). Finally, the unlisted ADRs were analyzed by using the Naranjo probability algorithm. Telogen effluvium, thrombocytopenia, restless leg syndrome and hypersexuality were found with the use of lurasidone and fall under the unlisted category. The causality assessment has shown a probable correlation of lurasidone with hypersexuality, restless leg syndrome, thrombocytopenia and possible relation with telogen effluvium. In conclusion, lurasidone is a novel and efficacious pharmacological treatment for bipolar depression and schizophrenia. However, more data regarding the safety of this drug in a large population is needed.

show abstract

Severe Extrapyramidal Syndrome Caused by Lurasidone Low Dose

Cited by 4 publications

References 3 publications

Can Isolated Head Tremors Be an Extrapyramidal Symptom Associated with Lurasidone?—A Case Series

Can Isolated Head Tremors Be an Extrapyramidal Symptom Associated with Lurasidone?—A Case Series

Lurasidone

Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression

Contact Info

Product

Resources

About